{"id":"NCT01527370","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)","officialTitle":"A Phase III Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in India","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-31","primaryCompletion":"2013-04-09","completion":"2013-04-09","firstPosted":"2012-02-07","resultsPosted":"2013-12-30","lastUpdate":"2018-09-18"},"enrollment":250,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster","Shingles"],"interventions":[{"type":"BIOLOGICAL","name":"Zoster Vaccine Live","otherNames":["ZOSTAVAX™","V211"]}],"arms":[{"label":"Zoster Vaccine Live","type":"EXPERIMENTAL"}],"summary":"This study will determine if ZOSTAVAX™ is safe, tolerable, and immunogenic in healthy adults in India.","primaryOutcome":{"measure":"The Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody at 6 Weeks Postvaccination","timeFrame":"Prevaccination up to 6 weeks postvaccination","effectByArm":[{"arm":"Zoster Vaccine Live","deltaMin":149.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["31325263"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":250},"commonTop":["Injection site erythema","Injection site swelling","Injection site pain"]}}